Drug intelligence / Profile preview

SIR-T CD19xCD22

Development stage: Preclinical
Lead developer: Angeles Therapeutics
Modality: Cell Therapies
Administration: Intravenous

Overview

SIR-T CD19xCD22 is a preclinical-stage bispecific cell therapy being developed by Angeles Therapeutics for the treatment of B-cell malignancies. The therapy utilizes the company's proprietary Synthetic Immune Receptor (SIR-T) platform, which is designed to engineer T cells with enhanced signaling and persistence compared to traditional CAR-T cells. By simultaneously targeting two distinct B-cell antigens, CD19 and CD22, SIR-T CD19xCD22 aims to mitigate the risk of antigen escape and improve durable response rates in patients with leukemia or lymphoma.

Other names: SIR-T CD19/CD22

Targets

CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)

Beyond the preview

Go deeper on SIR-T CD19xCD22.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIR-T CD19xCD22.

Explore the full profile